Member Info for marik

It's yesterdays news from the website update. Also a few negative chaps are busy with AVCT today.

Can't believe it @coolfree, the level that you guys stoop to. @Tony it's such a shame you have to deal with these kind of comments.

Todays RNS brings in focus the market worth:

preCISION can be widely applied to a range of other chemotherapies in a market worth $56.5B

This is what todays RNS is about. Potential for a pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $bn pa.

Including but not limited to:
• Pre|CISION pro-proteasome inhibitor
• Pre|CISION Paclitaxel
• Pre|CISION Oxaliplatin
• Pre|CISION Gemcitabine
• Pre|CISION Capecitabine
• Pre|CISION PARP inhibitor
• Pre|CISION PD-1 Inhibitor
• Pre|CISION AKT inhibitor
• Pre|CISION Balixafortide

@JDF7 as you are aware and so are those who are investing in Avacta, this is a platform technology. The preCISION chemistry validation will imply multiple drugs will become part of the Avacta pro-drug line up. That in itself is the value driver at this point in time.

It's all a matter of perspective here. The larger institutional or private stakeholders will be watching preCISION very carefully. Todays news provides for me the biggest indication of what AVA6000 results will be and creates the room/time to deploy capital as necessary.

Expecting some order filling very soon.

AVA3996 has shown excellent promise following "efficacy studies in several liquid and solid tumour models, safety studies".

It is the second prodrug entering the pipeline and endorses pre|Cision and the first prodrug AVA6000.

Just to put some perspective on this, Avacta are progressing with the "first proteasome inhibitor to be suitable for treating solid tumours". This is described by EVERYONE in the industry as "the holy grail".

We've just had news "**Second** pre|CISION Pro-drug Candidate Selected", that also endorses the current dose escalation preCISION drug AVA6000.

That's a very strong RNS.

We've just received possibly one of the most pivotal RNS for the company - i.e. the platform that Avacta are using works.

Prognosis with those with multiple myeloma is just over 50%, the chemotherapy for which is extremely toxic. AVA3996 will be "the first proteasome inhibitor to be suitable for treating solid tumours, thereby significantly increasing the market opportunity".

That's a resounding yes to AVA6000 and preCision.

@poirot it is huge news. preCision platform is working! AVA6000 must be doing well otherwise they wouldn't push ahead with this. I'm not surprised that Trinity Delta put such high price tag on the Tx.

Excellent news. Provides a resounding endorsement for ava6000. Absolutely brilliant.

May prove useful with its own thread:

Synairgen raised £80m in Oct 2020.

The gross proceeds were to:

1. fund a Phase III clinical trial of SNG001 in c. 900 COVID-19 patients (note on c 620 actually required, surplus funds available).

2. fund SNG001 manufacturing and device scale up producing c. 100,000 treatment courses per month in 2021

3. generate further data to support SNG001 clinical development, manufacturing processes and regulatory activities;

4· strengthen the balance sheet for potential partnering discussions with regards to the SNG001 opportunity, working capital and fees

I've mentioned this in the past on other platforms; there is plenty left in the bank (only 620 patients), and manufacturing scale up is already completed or near completion. With enough capital to put a large amount of the cogs in place. On successful data:

Regulatory news will follow a rough outline:

. First RNS = results + hint of partnerships (see Point 4 above) + mention of EUA

.Second RNS which will detail manufacturing in the pipeline and partnerships for full distribution.

. Third RNS will confirm EUA.

As Richard pointed out, we are talking months not years.

@Manifesto, Synairgen raised £80m in Oct 2020.

The gross proceeds were to:

1. fund a Phase III clinical trial of SNG001 in c. 900 COVID-19 patients (note on c 620 actually required, surplus funds available).

2. fund SNG001 manufacturing and device scale up producing c. 100,000 treatment courses per month in 2021

3. generate further data to support SNG001 clinical development, manufacturing processes and regulatory activities;

4· strengthen the balance sheet for potential partnering discussions with regards to the SNG001 opportunity, working capital and fees

I've mentioned this on the past on other platforms; there is plenty left in the bank (only 620 patients), and manufacturing scale up is already completed or near completion. With enough capital to put a large amount of the cogs in place.

Regulatory news will follow a rough outline:

. First RNS = results + hint of partnerships (see Point 4 above) + mention of EUA

.Second RNS which will detail manufacturing in the pipeline and partnerships for full distribution.

. Third RNS will confirm EUA.

As Richard pointed out, we are talking months not years.

Russia vs USSR (LOL):

Rocky Balboa says "No"
James "Clubber" Lang says "I pity the fool who..."

The antibody swap required, is something which Abingdon are more than capable of doing. Glancing at some of the comments above I've realised that we are not all on the same page. This discrepancy in well thought out and researched investments was also previously on show when the mere presence of antibodies in the test caught some off guard. It certainly explains why this was oversold.

"That is massive" - yes it is :-O

Topline data due very soon will validate the pre|Cision platform and bring a host of pro-drugs within the Avacta pipeline. That's the rerate and will move upwards.

You're welcome. I've been following the news from Synairgen for a long time and they tend to be very media shy. Very different right now.

Apologies if this has already been posted. This looks like a very positive video on Synairgen by RM, SH et al.,

https://www.youtube.com/watch?v=6lxZOocBz1g

Whoever is doing the media for SNG are doing a terrific job probably Brooke S Clarke.

"Have you seen the press pack on the website? Speaks volumes."

@Fruitsnveg It certainly does speak volumes and I had assumed that others had seen it before. However, here it is for reference:

https://www.synairgen.com/media/resources

They are really gearing up for news. We'll find out in due course.

Really pleased for everyone here.

GLA